In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $28.87, marking a +0.7% move from the previous day. This move lagged the S&P 500's daily gain of 1.59%. Meanwhile, the Dow ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year.

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

Global Retirement Partners LLC trimmed its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 19.8% during the ...

However, there are many contenders in the works. One of the most promising GLP-1 contenders is VK2735, a dual GLP-1/GIP ...

Citi analyst David Lebowitz maintained a Hold rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $38.00.

Truist Financial analyst Joon Lee maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today. The company’s shares closed ...

In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other oversold biotech stocks to buy now. Biotechnology stocks are among the most ...